COVID-19 vaccine players will split $100B in sales and $40B in profits, with Moderna leading the way: analyst

When longtime Evercore ISI pharma analyst Josh Schimmer realized that investors were struggling to place valuations on the leading COVID-19 vaccine developers, he pulled out the proverbial envelope, scribbled out some basic assumptions and issued predictions on Tuesday about just how profitable their endeavors might be.